This includes development of novel approaches to treatment with, for example, FasL-fused humanized antibodies to sensitize target cells to cell death [108,109,110] as suggested in glaucoma treatment [111,112], novel forms of RNA therapy [113], prognosis of long-term allergic outcomes at birth [114] or even for schizophrenia treatment [115]. This evidence concerns the gene FASLG and glaucoma.